Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

Researchers focus on parrots, poultry and phage therapy
2014-10-10

Photo: en.wikipedia

Veterinary biotechnology focuses on microbial and molecular biological approaches to veterinary illnesses. The group working on veterinary biotechnology research at the University of the Free State (UFS) consists of two academic staff members, Prof Rob Bragg and Dr Charlotte Boucher, two post-doctoral fellows, Drs Chris Theron and Arina Hitzeroth, five PhD and three honours students.

The group has three research focus areas.

Dr Boucher says, “Our main focus area is infectious coryza in poultry, caused by the bacterium Avibacterium paragalliarum. The aim is the control of the disease, mainly through improvement of vaccines, understanding the immune response and improved biosecurity. A key objective is improving methods for serotyping; studying of selected surface antigens and investigating the influence recently discovered bacteriophages might have on virulence. We have co-operative projects with research groups in China, India and Israel.

“The second focus area is an expression system co-developed with the National Institute for Agronomic Research (INRA), France. The flagship project is the expression of the coat protein gene of the beak and feather disease virus, a disease affecting parrots, currently threatening the endangered Cape parrot. This system has led to the development of serological tests, currently under patenting. The application of this system has been extended to human-related diseases, with two interdisciplinary projects underway, co-working with Profs Muriel Meiring and Felicity Burt. Prof Meiring is working on diseases causing bleeding disorders, such as blood-clotting impairment, while Prof Burt is working on viral infections causing haemorrhagic (bleeding) disorders.

“We are also researching disease control in a post-antibiotic era, investigating the potential of phage-therapy by targeting and destroying pathogenic islands within a host, with reduced side-effects on the host itself.

“We have smaller projects, including an interdisciplinary project with Zoology, looking at the protein profile of amphibian (frog) secretions with the focus on antimicrobial activity, as these secretions assist with protecting amphibian skin against infections.”  


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept